The primary goal of this proposal is to establish the role of proteoglycans in tumor formation. Studies on the neoplastic behavior of proteoglycan-deficient mutants of Chinese hamster ovary (CHO) cells indicate that CHO cells require heparan sulfate proteoglycans to form subcutaneous tumors in nude mice. Additional experiments using other CHO cell mutants are proposed to learn more about the structural features of the proteoglycans required for tumor proliferation. Intravenous injection of cells should reveal if proteoglycans are also needed for tumor formation in the lungs, liver and other tissues. Transfection experiments in which proteoglycans foreign to CHO cells are expressed will help distinguish if core proteins or the glycosaminoglycan chains are required for tumor formation. As a corollary to these studies, compounds that inhibit proteoglycan synthesis will be tested as inhibitors of tumor formation. To gain insight into the organization and metabolism of tumor proteoglycans, chemical, radiochemical, and immunological studies of tumor proteoglycans derived from wild-type cells and mixtures of wild-type and mutant cells are proposed. Parallel studies of CHO cell aggregates will be conducted to examine if differences in proteoglycan metabolism in tumors and cells is due to cell aggregation. A long-range goal of this proposal is to determine whether viral transformation of CHO cells with Rous sarcoma virus affects the requirement for proteoglycans. To determine if other cells require proteoglycans for tumor formation, the isolation of mouse 3T3 cell mutants defective in proteoglycan synthesis will be attempted.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA046462-05
Application #
2092158
Study Section
Physiological Chemistry Study Section (PC)
Project Start
1990-04-20
Project End
1996-03-31
Budget Start
1994-04-01
Budget End
1996-03-31
Support Year
5
Fiscal Year
1994
Total Cost
Indirect Cost
Name
University of Alabama Birmingham
Department
Biochemistry
Type
Schools of Dentistry
DUNS #
004514360
City
Birmingham
State
AL
Country
United States
Zip Code
35294
Brown, Jillian R; Yang, Feng; Sinha, Anjana et al. (2009) Deoxygenated disaccharide analogs as specific inhibitors of beta1-4-galactosyltransferase 1 and selectin-mediated tumor metastasis. J Biol Chem 284:4952-9
Moinpour, Carol M; Donaldson, Gary W; Nakamura, Yoshio (2009) Chemotherapeutic impact on pain and global health-related quality of life in hormone-refractory prostate cancer: Dynamically Modified Outcomes (DYNAMO) analysis of a randomized controlled trial. Qual Life Res 18:147-55
Schuksz, Manuela; Fuster, Mark M; Brown, Jillian R et al. (2008) Surfen, a small molecule antagonist of heparan sulfate. Proc Natl Acad Sci U S A 105:13075-80
Brown, Jillian R; Crawford, Brett E; Esko, Jeffrey D (2007) Glycan antagonists and inhibitors: a fount for drug discovery. Crit Rev Biochem Mol Biol 42:481-515
Moinpour, Carol M; Donaldson, Gary W; Redman, Mary W (2007) Do general dimensions of quality of life add clinical value to symptom data? J Natl Cancer Inst Monogr :31-8
Petrylak, Daniel P; Ankerst, Donna Pauler; Jiang, Caroline S et al. (2006) Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16. J Natl Cancer Inst 98:516-21
Brown, Jillian R; Fuster, Mark M; Li, Ruixia et al. (2006) A disaccharide-based inhibitor of glycosylation attenuates metastatic tumor cell dissemination. Clin Cancer Res 12:2894-901
Petrylak, Daniel P; Tangen, Catherine M; Hussain, Maha H A et al. (2004) Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351:1513-20
Ben-Zaken, Olga; Tzaban, Salit; Tal, Yuval et al. (2003) Cellular heparan sulfate participates in the metabolism of prions. J Biol Chem 278:40041-9
Fuster, Mark M; Brown, Jillian R; Wang, Lianchun et al. (2003) A disaccharide precursor of sialyl Lewis X inhibits metastatic potential of tumor cells. Cancer Res 63:2775-81

Showing the most recent 10 out of 30 publications